Table IV.

Responses by EBMT Criteria and Other Evidence of Activity.

Category	Tanespimycin dose, mg/m2
	150 n = 4	220 n = 9	275 n = 3	340 n = 7	420 n = 3	525 n = 3	All dose cohorts N = 29
Minimal response, n (%)	1 (25)	0	0	0	0	0	1 (3)
Stable disease, n (%)	2 (50)	5 (56)	3 (100)	3 (43)	1 (33)	1 (33)	15 (52)
Progression of disease, n (%)	1 (25)	4 (44)	0	3 (43)	2 (67)	1 (33)	11 (38)
Missing, n (%)	0	0	0	1 (14)	0	1 (33)	2 (7)
Decrease in M protein, n	1	0	1	2	0	0	4
Decrease in M spike, %	33		11	20, 11
Decrease in urinary M protein, %	41		12	91, 43

EBMT, the European Group for Blood and Marrow Transplantation.